{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-076795","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.952388+00:00","generated_at":"2026-06-17T21:38:05.533731+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics in-licenses Dr. Reddy's Abatacept biosimilar for COYA 302; $350K upfront, up to $22.7M milestones","bullets":["Exclusive License and Supply Agreement with Dr. Reddy's for Abatacept biosimilar, effective April 1, 2023.","Upfront payment of $350,000; potential development, regulatory and sales milestones up to ~$22.7 million.","COYA 302 combines Coya's low-dose IL-2 (COYA 301) with the biosimilar for neurodegenerative diseases.","Coya responsible for development; Dr. Reddy's for manufacture and supply of biosimilar.","Agreement covers U.S., Canada, Mexico, South America, EU, UK, Japan; cross-license for COYA 301 in other territories."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-076795","json":"https://secwatch.observer/filing/0001193125-23-076795.json","markdown":"https://secwatch.observer/filing/0001193125-23-076795.md","text":"https://secwatch.observer/filing/0001193125-23-076795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/0001193125-23-076795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/d429716d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:38:05.533731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bf726f226189f489b1f21a3d2f590c3fb624f10","claim":"Coya Therapeutics, Inc. entered into License Agreement with Dr. Reddy's Laboratories Limited valued at $350,000 (effective 2023-03-16).","evidence_excerpt":"On March16, 2023, Coya Therapeutics, Inc. (the “Company”) entered into an exclusive License and Supply Agreement (the “License Agreement”) with Dr. Reddy’s Laboratories Limited (“DRL”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/0001193125-23-076795-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Dr. Reddy's Laboratories Limited"},{"label":"Value","value":"$350,000"},{"label":"Effective","value":"2023-03-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}